Contents

Search

triamcinolone (TAC, Arsitospan, Kenalog, Trivaris)

Systemic agent: Tradenames: Aristocort, Kenacort, Kenalog. Indications: - anti-inflammatory agent (systemic, topical) Dosage: 1) 4-48 mg PO/IM QD 2) 20 mg injected into large joints 3) 5-10 mg into smaller joints Tabs: 1, 2, 4, 8 mg Syrup: 4 mg/5 mL. Injection: Kenalog, Trivaris Adverse effects: 1) common (> 10%) - increased appetite, insomnia, indigestion, nervousness 2)less common (1-10%) - cataracts, hyperglycemia (diabetes mellitus), hirsutism, joint pain, epistaxis 3) uncommon (< 1%) - seizures, mood swings, headache, skin atrophy, bruising, hyperpigmentation, acne, amenorrhea, Na+ & H20 retention, Cushing's syndrome, suppression of bone growth, abdominal distension, ulcerative esophagitis, pancreatitis, muscle wasting, hypersensitivity, delirium, hallucinations, euphoria 4) short-term - fluid & electrolyte disturbances - hyperglycemia - poor wound healing - GI disturbances - spread of infection 5) long-term - osteoporosis - bone fractures - pituitary adrenal axis insufficiency - Cushing's syndrome - acute adrenal insufficiency with rapid withdrawal of therapy - skin atrophy - hyperpigmentation Drug interactions: 1) aminoglutethimide 2) anticholinesterases 3) barbiturates 4) carbamazepine 5) phenytoin 6) rifampin 7) live virus vaccines Mechanism of action: - intermediate-acting glucocorticoid

Interactions

drug interactions drug adverse effects (more general classes) monitor with drug (more general classes)

Specific

Triamcinolone Inhalation (Azmacort) Triamcinolone Nasal (Nasocort) Triamcinolone Topical (Aristocort, Kenacort)

General

antiasthmatic agent antipruritic agent glucocorticoid

Properties

MISC-INFO: elimination route LIVER pregnancy-category C D safety in lactation - ? ?

Database Correlations

PUBCHEM correlations

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 85.
  3. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  4. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 743
  5. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  6. Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
  7. Journal Watch, Mass Med Soc 20(11):88 (June) 2000 - Wong CA, Walsh LJ, Smith CJ et al Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet. 2000 Apr 22;355(9213):1399-403 PMID: 10791523 - Sambrook PN Inhaled corticosteroids, bone density, and risk of fracture. Lancet 355:1385, 2000 PMID: 10791519

Component-of

bupivacaine/lidocaine/povidone iodine/triamcinolone dimethicone/triamcinolone inhalation agent/lidocaine/povidone iodine/triamcinolone lidocaine/povidone iodine/triamcinolone neomycin/nystatin/thiostrepton/triamcinolone nystatin/triamcinolone (Mycolog II, Mycogen II, Tri-Statin II)